The stock of Lannett Company, Inc. (NYSE:LCI) is a huge mover today! About 512,238 shares traded hands. Lannett Company, Inc. (NYSE:LCI) has risen 11.93% since April 28, 2016 and is uptrending. It has outperformed by 6.00% the S&P500.
The move comes after 6 months positive chart setup for the $880.50M company. It was reported on Dec, 1 by Barchart.com. We have $24.86 PT which if reached, will make NYSE:LCI worth $35.22M more.
Analysts await Lannett Company, Inc. (NYSE:LCI) to report earnings on February, 1. They expect $0.83 earnings per share, down 12.63% or $0.12 from last year’s $0.95 per share. LCI’s profit will be $30.58M for 7.20 P/E if the $0.83 EPS becomes a reality. After $0.77 actual earnings per share reported by Lannett Company, Inc. for the previous quarter, Wall Street now forecasts 7.79% EPS growth.
Lannett Company, Inc. (NYSE:LCI) Ratings Coverage
Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm earned “Strong-Buy” rating on Monday, September 7 by Zacks. TH Capital maintained it with “Buy” rating and $68.0 target price in Thursday, September 3 report. The firm has “Outperform” rating by Raymond James given on Wednesday, August 24. Roth Capital maintained the shares of LCI in a report on Thursday, March 24 with “Buy” rating. The stock of Lannett Company, Inc. (NYSE:LCI) has “Buy” rating given on Thursday, September 3 by Roth Capital. Roth Capital maintained Lannett Company, Inc. (NYSE:LCI) on Friday, March 11 with “Buy” rating. The stock has “Hold” rating given by Craig Hallum on Thursday, November 5. On Thursday, August 27 the stock rating was maintained by Craig Hallum with “Buy”. Craig Hallum upgraded the shares of LCI in a report on Thursday, February 4 to “Buy” rating. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Positive” rating by Susquehanna on Tuesday, July 21.
According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”
Insitutional Activity: The institutional sentiment increased to 1.36 in 2016 Q2. Its up 0.48, from 0.88 in 2016Q1. The ratio improved, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.
Cubist Systematic Strategies Lc, a Connecticut-based fund reported 1,880 shares. Great West Life Assurance Can owns 2,000 shares or 0% of their US portfolio. Ls Inv Advisors Limited Liability Corporation reported 1,169 shares or 0% of all its holdings. Comerica Financial Bank last reported 0.01% of its portfolio in the stock. Principal Fin last reported 0.01% of its portfolio in the stock. The Iowa-based At Bancshares has invested 0.4% in Lannett Company, Inc. (NYSE:LCI). Macquarie Grp holds 0% or 34,600 shares in its portfolio. Texas Permanent School Fund has invested 0.01% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Dupont Capital owns 82,305 shares or 0.04% of their US portfolio. Moreover, Raymond James & Assoc has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 8,820 shares. Hutchin Hill Lp holds 0.06% or 73,700 shares in its portfolio. New York State Teachers Retirement holds 0% or 54,293 shares in its portfolio. State Common Retirement Fund holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 68,247 shares. The Pennsylvania-based Tfs Ltd Liability Com has invested 0.09% in Lannett Company, Inc. (NYSE:LCI). Zurcher Kantonalbank (Zurich Cantonalbank) has 670 shares for 0% of their US portfolio.
Insider Transactions: Since August 31, 2016, the stock had 0 buys, and 3 insider sales for $416,823 net activity. Landis G. Michael had sold 6,786 shares worth $226,716 on Wednesday, August 31. On Thursday, September 1 Maher James M. sold $50,119 worth of the stock or 1,478 shares.
LCI Company Profile
Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.